Serum IL-1β Predicts De Novo Hepatitis B Virus Reactivation During Direct-Acting Antiviral Therapy for Hepatitis C, Not During Anti-Cancer/Immunosuppressive Therapy

Investigators evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and direct-acting antiviral.